Commitments and Contingencies - Additional Information (Details) - USD ($)						12 Months Ended
	Oct. 20, 2023	Mar. 17, 2023	Jan. 09, 2017	Aug. 17, 2015	Jan. 13, 2015	Dec. 31, 2024	Dec. 31, 2023	Apr. 03, 2023	Dec. 31, 2022	Oct. 22, 2019	Oct. 05, 2018	Aug. 24, 2004
Accrued Payments
Research and development expense						$ 362,000	$ 16,279,000
Revenue						$ 10,000	$ 5,000
Warrant exercise per share						$ 28.5	$ 268.5		$ 863.25
Loss contingency, name of plaintiff		KBI Biopharma
Unspecified monetary damages		$ 3,200,000
Litigation expense	$ 1,000,000
Md Anderson Warrant [Member]
Accrued Payments
Number of warrants										22,222
Warrant exercise per share										$ 0.15
Warrant expiry date										Dec. 31, 2026
MD Anderson Related to the 2015 R&D Agreement [Member]
Accrued Payments
Clinical expenses						$ 0	$ 0.1
MD Anderson License and the Research and Development Agreement [Member]
Accrued Payments
Reimbursement of historical costs										$ 20,000,000
Clinical expenses						0	800,000
Aggregate potential benchmark payments										36,500,000
Payments due prior to the first marketing approval										$ 3,000,000
CRADA Agreement [Member]
Accrued Payments
Agreement termination date			Oct. 13, 2023
Annual expense incurred						0	500,000
MD Anderson Agreement and Worldwide License [Member]
Accrued Payments
License agreement commencing date					Jan. 13, 2015
The University of Texas MD Anderson Cancer Center and The Texas A & M University System [Member]
Accrued Payments
Milestone maximum payment												$ 4,500,000
The University of Texas MD Anderson Cancer Center and The Texas A & M University System [Member] | Royalty [Member]
Accrued Payments
Payment under license agreement						$ 0	1,000
License Agreement with the National Cancer Institute [Member]
Accrued Payments
Agreement termination effective date						Dec. 26, 2023
License expense						$ 0	400,000
Collaboration Agreement with Solasia Pharma KK [Member]
Accrued Payments
Revenue						0	0
Collaboration Agreement with Solasia Pharma KK [Member] | Royalty [Member]
Accrued Payments
Revenue						$ 10,000	$ 5,000
Intrexon Corporation [Member]
Accrued Payments
Annual license fee								$ 75,000			$ 100,000
Expected additional milestones payable											52,500,000
Intrexon Corporation [Member] | T-Cell Receptor [Member]
Accrued Payments
Maximum royalty amount											$ 100,000,000
Portion of income payable to related party											20.00%
Minimum [Member] | MD Anderson License and the Research and Development Agreement [Member]
Accrued Payments
Research and development expense				$ 15,000,000
Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member]
Accrued Payments
Research and development expense				$ 20,000,000